Physician profile
Nimer Mian
NPI 1518084631
$6,445.17
in general payments reported to CMS, 2019-2025
44 companies · $1,271 in 2025
The $1,271 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $459 · 2021: $789 · 2022: $873 · 2023: $1,073 · 2024: $1,021 · 2025: $1,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,365.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $939.50 | 2021-2025 | |
| Ucb, INC. | $733.53 | 2019-2025 | Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $685.84 | 2019-2025 | |
| Eisai INC. | $585.05 | 2019-2025 | |
| Sk Life Science, INC. | $419.25 | 2020-2025 | |
| Lilly USA, LLC | $386.34 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Pfizer INC. | $338.18 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $290.99 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Amgen INC. | $216.46 | 2019-2023 | Aimovig |
| Biogen, INC. | $161.80 | 2019-2023 | Vumerity, Tysabri |
| Aucta Pharmaceuticals, INC. | $149.62 | 2024-2025 | Motpoly Xr |
| Neurelis, INC. | $146.73 | 2021-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $114.30 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $105.11 | 2019-2020 | |
| Argenx US, INC. | $100.74 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimer Mian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.